Valsartan
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Valsartan: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Valsartan is an Angiotensin II Receptor Blocker (ARB) whose established pharmacological class effect is the treatment of hypertension. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, but this direction is currently supported by only 1 preclinical/animal-model publication and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (specific TFDA/MHRA licensed indication text not available in this Evidence Pack — see Data Gaps) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold (Research Question stage) |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Valsartan is currently flagged as a High-severity data gap in the Evidence Pack. However, the underlying repurposing rationale confirms that Valsartan acts as an Angiotensin II Receptor Blocker (ARB), directly blocking the AT1 receptor within the renin-angiotensin-aldosterone system (RAAS) — this is consistent with its established class-level antihypertensive effect.
Malignant renovascular hypertension is a severe hypertensive subtype driven substantially by excessive renin-angiotensin activation and renal vascular pathology. Given that AT1 receptor blockade is already a well-established mechanism for blood pressure control, extending this class effect to a more severe, renin-driven hypertensive phenotype is mechanistically plausible.
The single supporting publication (Hilgers et al., Circulation, 2001) found that AT1 receptor blockade prevented lethal malignant hypertension in an animal model, and notably did so independently of blood-pressure-lowering effects — pointing to a renoprotective, anti-inflammatory mechanism rather than simple haemodynamic control. This strengthens biological plausibility but remains a single preclinical study; it does not establish clinical efficacy in humans.
Clinical Trial Evidence
Currently no related clinical trials registered for this predicted indication (Malignant Renovascular Hypertension).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11560862 | 2001 | Preclinical/Animal | Circulation | AT1 receptor blockade prevented lethal malignant hypertension in an animal model, independent of blood-pressure-lowering effect, and was linked to reduced kidney inflammation |
UK Market Information
No marketing authorisation records are present in the current Evidence Pack. Valsartan is recorded as Not marketed in this dataset, with 0 total licences on file. Licence and formulation data will need to be sourced separately (e.g. MHRA product register, BNF) before any market-facing assessment can proceed.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(No key warnings, contraindications, or drug–drug interaction data were returned in the current Evidence Pack query.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the Malignant Renovascular Hypertension indication is currently limited to a single 2001 animal-model publication (Evidence Level L4, decision stage S1 — Research Question). There are no clinical trials, human observational data, or licensing information to support progression at this time.
To proceed, the following is needed:
- TFDA/MHRA SmPC warnings and contraindications (Blocking data gap — DG001)
- Detailed mechanism of action (MOA) data from DrugBank (High-priority data gap — DG002)
- Human clinical or observational evidence (ideally Phase 2/3) specific to malignant or renovascular hypertension populations
- UK marketing authorisation and licence data, given the drug is currently recorded as not marketed
Note: Within this same Evidence Pack, a different candidate indication for Valsartan — chronic pulmonary heart disease (cor pulmonale) — carries substantially stronger evidence (Evidence Level L3, decision stage S2, “Proceed with Guardrails”), supported by a completed Phase 4 RCT (Sacubitril/Valsartan vs Enalapril, NCT02768298) and multiple COPD-with-heart-failure cohort analyses from the PARADIGM-HF and PARAGON-HF trial programmes. This indication may warrant separate, prioritised evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.